{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T18:17:29Z","timestamp":1774376249450,"version":"3.50.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.breast.2005.08.033","type":"journal-article","created":{"date-parts":[[2005,10,18]],"date-time":"2005-10-18T07:21:09Z","timestamp":1129620069000},"page":"301-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Comparative assessment of lipid effects of endocrine therapy for breast cancer: Implications for cardiovascular disease prevention in postmenopausal women"],"prefix":"10.1016","volume":"15","author":[{"given":"F.J.","family":"Esteva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.N.","family":"Hortobagyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2005.08.033_bib1","unstructured":"National Center for Chronic Disease Prevention and Health Promotion. http:\/\/www.cdc.gov\/nccdphp\/bb_heartdisease\/index.htm 2004."},{"key":"10.1016\/j.breast.2005.08.033_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0002-8703(86)90155-9","article-title":"Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population","volume":"111","author":"Lerner","year":"1986","journal-title":"Am Heart J"},{"key":"10.1016\/j.breast.2005.08.033_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0091-7435(91)90006-P","article-title":"Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence","volume":"20","author":"Stampfer","year":"1991","journal-title":"Prev Med"},{"key":"10.1016\/j.breast.2005.08.033_bib4","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/oxfordjournals.eurheartj.a015034","article-title":"Failure to demonstrate myocardial ischaemia in patients with angina and normal coronary arteries. Evaluation by continuous coronary sinus pH monitoring and lactate metabolism","volume":"17","author":"Rosano","year":"1996","journal-title":"Eur Heart J"},{"key":"10.1016\/j.breast.2005.08.033_bib5","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/jnci\/djh216","article-title":"Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk","volume":"96","author":"Furberg","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2005.08.033_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2005.08.033_bib7","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2005.08.033_bib8","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2005.08.033_bib9","series-title":"Cancer medicine","first-page":"743","article-title":"Estrogens and antiestrogens","author":"Jordan","year":"2000"},{"key":"10.1016\/j.breast.2005.08.033_bib10","first-page":"59","article-title":"Adjuvant tamoxifen in breast cancer treatment in postmenopausal women: occurrence of thromboembolic complications","volume":"1","author":"Cutuli","year":"1994","journal-title":"Oncol Rep"},{"key":"10.1016\/j.breast.2005.08.033_bib11","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","article-title":"Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors","volume":"88","author":"Fisher","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2005.08.033_bib12","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2005.08.033_bib13","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1046\/j.1365-2125.1998.00733.x","article-title":"Tamoxifen and risk of idiopathic venous thromboembolism","volume":"45","author":"Meier","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.breast.2005.08.033_bib14","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/00001813-199711000-00002","article-title":"Acquired tamoxifen resistance in human breast cancer\u2014potential mechanisms and clinical implications","volume":"8","author":"Johnston","year":"1997","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.breast.2005.08.033_bib15","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.2003.07.071","article-title":"Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer","volume":"21","author":"Partridge","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2005.08.033_bib16","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","article-title":"Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment","volume":"20","author":"Howell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2005.08.033_bib17","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","article-title":"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial","volume":"20","author":"Osborne","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2005.08.033_bib18","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2005.08.033_bib19","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","article-title":"Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study","volume":"18","author":"Bonneterre","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2005.08.033_bib20","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y","article-title":"Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma","volume":"92","author":"Bonneterre","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2005.08.033_bib21","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0959-8049(03)00326-5","article-title":"Anastrozole (Arimidex\u2122) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results","volume":"39","author":"Nabholtz","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2005.08.033_bib22","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1200\/JCO.1996.14.7.2000","article-title":"Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group","volume":"14","author":"Buzdar","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2005.08.033_bib23","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.0.CO;2-5","article-title":"Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group","volume":"83","author":"Buzdar","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2005.08.033_bib24","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","article-title":"Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group","volume":"19","author":"Mouridsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2005.08.033_bib25","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1200\/JCO.2001.19.14.3357","article-title":"Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate","volume":"19","author":"Buzdar","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2005.08.033_bib26","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2003.04.194","article-title":"Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group","volume":"21","author":"Mouridsen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2005.08.033_bib27","unstructured":"European Organisation for Research and Treatment of Cancer. EORTC protocols. http:\/\/www.eortc.be\/protoc\/listprot.asp?kind=group&grp=2 2004. 18-3-0004."},{"key":"10.1016\/j.breast.2005.08.033_bib28","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1200\/JCO.2000.18.7.1399","article-title":"Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group","volume":"18","author":"Kaufmann","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2005.08.033_bib29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2005.08.033_bib30","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial","volume":"359","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2005.08.033_bib31","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/cncr.11745","volume":"98","year":"2003","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.breast.2005.08.033_bib32","first-page":"S3","article-title":"BIG 1-98: a prospective randomized double-blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer","volume":"14","year":"2005","journal-title":"The Breast"},{"key":"10.1016\/j.breast.2005.08.033_bib33","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.breast.2005.08.033_bib34","first-page":"S7","article-title":"Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial","volume":"88","author":"Jakesz","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2005.08.033_bib35","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1200\/JCO.2005.04.120","article-title":"Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial","volume":"23","author":"Boccardo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2005.08.033_bib36","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2005.08.033_bib37","first-page":"87","article-title":"Updated analysis of the NCIC CTG MA17 randomized placebo (P) controlled trial of letrozole (L) after 5 years of tamoxifen in postmenopausal women with early stage breast cancer","volume":"23","author":"Goss","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"16s part I of II","key":"10.1016\/j.breast.2005.08.033_bib38","first-page":"10s","article-title":"Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a)","volume":"23","author":"Jakesz","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.breast.2005.08.033_bib39","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1001\/jama.1987.03390160062027","article-title":"Cholesterol and mortality. 30 years of follow-up from the Framingham study","volume":"257","author":"Anderson","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2005.08.033_bib40","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(86)90597-0","article-title":"Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men","volume":"2","author":"Martin","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2005.08.033_bib41","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0002-9149(80)90516-0","article-title":"Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols","volume":"46","author":"Wilson","year":"1980","journal-title":"Am J Cardiol"},{"issue":"Suppl","key":"10.1016\/j.breast.2005.08.033_bib42","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/0021-9150(96)05852-2","article-title":"High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport","volume":"124","author":"Assmann","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.breast.2005.08.033_bib43","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.breast.2005.08.033_bib44","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1001\/jama.1988.03410230074031","article-title":"The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study","volume":"260","author":"Abbott","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2005.08.033_bib45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.breast.2005.08.033_bib46","doi-asserted-by":"crossref","first-page":"3J","DOI":"10.1016\/S0002-9149(98)00423-8","article-title":"Current and future treatment of hyperlipidemia: the role of statins","volume":"82","author":"Farnier","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.breast.2005.08.033_bib47","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2005.08.033_bib48","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.1984.03340270043026","article-title":"The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2005.08.033_bib49","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.1986.03380200061022","article-title":"Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)","volume":"256","author":"Stamler","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2005.08.033_bib50","doi-asserted-by":"crossref","first-page":"7B","DOI":"10.1016\/S0002-9149(98)00031-9","article-title":"Hypertriglyceridemia as a cardiovascular risk factor","volume":"81","author":"Austin","year":"1998","journal-title":"Am J Cardiol"},{"issue":"Suppl M","key":"10.1016\/j.breast.2005.08.033_bib51","first-page":"M8","article-title":"The emergence of triglycerides as a significant independent risk factor in coronary artery disease","volume":"19","author":"Assmann","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.breast.2005.08.033_bib52","doi-asserted-by":"crossref","first-page":"18B","DOI":"10.1016\/S0002-9149(98)00033-2","article-title":"Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome","volume":"81","author":"Grundy","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.breast.2005.08.033_bib53","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0002-8703(03)00412-5","article-title":"Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen\/progestin Replacement Study (HERS)","volume":"146","author":"Shlipak","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.breast.2005.08.033_bib54","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF01811244","article-title":"Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels","volume":"12","author":"Bertelli","year":"1988","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2005.08.033_bib55","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/bmj.305.6847.225","article-title":"Long term effects of tamoxifen on blood lipid values in breast cancer","volume":"305","author":"Dewar","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.breast.2005.08.033_bib56","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/86.20.1534","article-title":"Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment","volume":"86","author":"Love","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2005.08.033_bib57","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF01806815","article-title":"Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer","volume":"40","author":"Morales","year":"1996","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2005.08.033_bib58","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1210\/jcem.83.5.4753","article-title":"Effect of tamoxifen on serum lipid metabolism","volume":"83","author":"Hozumi","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.breast.2005.08.033_bib59","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/1097-0142(19860601)57:11<2123::AID-CNCR2820571106>3.0.CO;2-2","article-title":"Severe lipemia induced by tamoxifen","volume":"57","author":"Brun","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2005.08.033_bib60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1023\/A:1023348021773","article-title":"Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction","volume":"79","author":"Liu","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2005.08.033_bib61","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","article-title":"Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial","volume":"93","author":"Fisher","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2005.08.033_bib62","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/978-3-642-55647-0_9","article-title":"Aromatase inhibitors in prevention\u2014data from the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study)","volume":"163","author":"Cuzick","year":"2003","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.breast.2005.08.033_bib63","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1359-6349(04)90900-7","article-title":"Anastrozole therapy and lipid profile: an update","volume":"2","author":"Wojtacki","year":"2004","journal-title":"Eur J Cancer Suppl"},{"issue":"Suppl","key":"10.1016\/j.breast.2005.08.033_bib64","first-page":"S51","article-title":"The effect of anastrozole (Arimidex\u2122) on serum lipids\u2014data from a randomized comparison of anastrozole (AN) vs Tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC)","volume":"64","author":"Dewar","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2005.08.033_bib65","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/S0959-8049(01)00155-1","article-title":"Effect of letrozole on the lipid profile in postmenopausal women with breast cancer","volume":"37","author":"Elisaf","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2005.08.033_bib66","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00713400","article-title":"Plasma changes in breast cancer patients during endocrine therapy\u2014lipid measurements and nuclear magnetic resonance (NMR) spectroscopy","volume":"36","author":"Engan","year":"1995","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2005.08.033_bib67","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/annonc\/mdh064","volume":"15","author":"Atalay","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2005.08.033_bib68","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.1998.16.2.453","article-title":"Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate","volume":"16","author":"Dombernowsky","year":"1998","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.breast.2005.08.033_bib69","first-page":"S31","article-title":"Effect of anastrozole and tamoxifen on serum lipid levels in Japanese postmenopausal women with early breast cancer","volume":"82","author":"Sawada","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2005.08.033_bib70","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1359-6349(04)90903-2","article-title":"Effects of anastrozole on the lipid profile in postmenopausal breast cancer patients\u2014a preliminary study","volume":"2","author":"Hozumi","year":"2004","journal-title":"Eur J Cancer Suppl"},{"issue":"Suppl 1","key":"10.1016\/j.breast.2005.08.033_bib71","first-page":"S156","article-title":"The effects of adjuvant anastrozole, exemestane, tamoxifen, and toremifene on serum lipids in postmenopausal women with breast cancer\u2014a randomised study","volume":"76","author":"Kataja","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2005.08.033_bib72","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJM199906103402306","article-title":"The protective effects of estrogen on the cardiovascular system","volume":"340","author":"Mendelsohn","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2005.08.033_bib73","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1001\/jama.291.24.2969","article-title":"Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction","volume":"291","author":"Schuit","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2005.08.033_bib74","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.290.17.2263","article-title":"Association between estrogen receptor alpha gene variation and cardiovascular disease","volume":"290","author":"Shearman","year":"2003","journal-title":"JAMA"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977605002249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977605002249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:22:17Z","timestamp":1760775737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977605002249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0960977605002249"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2005.08.033","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative assessment of lipid effects of endocrine therapy for breast cancer: Implications for cardiovascular disease prevention in postmenopausal women","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2005.08.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}